Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
|
|
- Gavin Byrd
- 8 years ago
- Views:
Transcription
1 Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
2 Workshop Over View Considerations/barriers to treatments in type 2 diabetes NICE recommendations Clinical application of these therapies in managing type 2 diabetes Group discussions on How & what to choose Feed back
3 Key Challenges of Type 2 Diabetes Diabetes is a progressive multi-system disease characterized by: Declining beta-cell function Deterioration of glycaemic control Increased risk of cardiovascular disease (including hypertension and coronary heart disease) Increase in body weight
4 The trade off! As diabetes treatments are added to improve glucose control, clinicians & patients face trade-offs such as: Hypoglycaemia Weight gain Complex treatment regimens
5 NICE guidelines Usual approach Alternatives NHS National Institute for Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes May 2009;87
6 GLP-1 Effects in Humans GLP-1 secreted upon the ingestion of food 5.Brain: promotes satiety and reduces appetite 4,5 2.α-cell: suppresses postprandial glucagon secretion 1 1.β-cell: enhances glucose-dependent insulin secretion in the pancreas 1 3.Liver: reduces hepatic glucose output 2 4.Stomach: slows the rate of gastric emptying 3 Adapted from 1 Nauck MA, et al. Diabetologia 1993;36: ; 2 Larsson H, et al. Acta Physiol Scand 1997;160: ; 3 Nauck MA, et al. Diabetologia 1996;39: ; 4 Flint A, et al. J Clin Invest 1998;101: ; 5 Zander et al. Lancet 2002;359:
7 Exenatide (Byetta) Commence on 5mcgs twice a day up to one hour before the 2 main meals of the day. Needs to be given at least 6 hours apart Increase to 10mcgs BD after one month 1 pen = one months treatment. Exenatide Summary of Product Characteristics 2006
8 Liraglutide(Victosa) Prefilled, disposable pen for s.c. injection Contains 18 mg liraglutide in 3 ml 0.6 m g selected 1.2 m g selected Once-daily s.c. injection Select dose (0.6, 1.2 or 1.8 mg) Inject at any time, independent of mealtimes (preferably same time each day) Start with 0.6mgs for 1 week increasing to 1.2 mgs there after 1.8 m g selected Victoza Summary of Product Characteristics
9 Exenatide 3 year extension study Open label extension study To evaluate the effects of 3 years exenatide therapy on glycaemic control, body weight, cardiometabolic markers and safety. Open-ended, open label extension of 3 placebo-controlled trials and their open label extensions. 217 adult type 2 diabetes patients: HbA 1c 11.0%, FPG <240 mg/dl, BMI 27-45kg/m 2, pre-study MET dose 1500 mg/d for 3 months, or at least the maximally tolerated effective dose of SU, or a combination. Klonoff DC et al. Curr Med Res Opin 2008; 24(1):
10 At 3 years Exenatide 10µg BD provided sustained reductions in HbA 1c in the completer population 46% of patients achieved HbA 1c 7% Klonoff DC et al. Curr Med Res Opin 2008; 24(1):
11 and progressive weight loss 84% of exenatide patients lost weight over 3 years of treatment 50% of patients lost at least 5% of baseline body weight Klonoff DC et al. Curr Med Res Opin 2008; 24(1):
12 Exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes Overview To compare effects of exenatide and insulin glargine on glycaemic control in patients with type 2 diabetes that is sub-optimally controlled with metformin (MET) and sulphonylurea (SU) 26-week treatment, BD fixed dose exenatide versus OD insulin glargine (titrate to fasting blood glucose level < 5.6 mmol/l) Primary endpoint: change in HbA 1c from baseline ITT sample: N = 549 randomised patients with 1 post-baseline measurement Heine R, et al. Ann Intern Med 2005;143:
13 Study design Randomised, open-label, controlled, multi-centre study in patients with type 2 diabetes failing to achieve adequate glycaemic control with metformin (MET) and sulphonylurea (SU) Screening (HbA 1c > 7.0% to <10.0%) Randomisation Current MET and SU therapy Exenatide 5 µg BD + MET and SU Exenatide 10 µg BD + MET and SU Insulin glargine + MET and SU (insulin titrated to target FPG < 5.6 mmol/l by daily monitoring) Time (weeks) Heine R, et al. Ann Intern Med 2005;143:
14 Change in HbA 1c over time, ITT population HbA 1c (%) Time (weeks) Exenatide, 10 μg (N = 275) Insulin glargine, mean dose at endpoint = 25.0 U/day (N = 260) ITT population: exenatide (N = 275) insulin glargine (N = 260), Mean ± SD shown Heine R, et al. Ann Intern Med 2005;143:
15 Change in body weight over time, ITT population kg Change in body weight (kg) * * * * * * -2.3 kg 4.1 kg Time (weeks) Exenatide (N = 275) Insulin glargine (N = 260) ITT population: exenatide (N = 275) insulin glargine (N = 260), Mean ± SD shown; * P < , exenatide versus insulin glargine at same time point Heine R, et al. Ann Intern Med 2005;143:
16 Summary Exenatide was as effective as titrated insulin Glargine in improving glycaemic control (based on HbA 1c measurement) in type 2 diabetes patients Exenatide was associated with progressive reductions in body weight Insulin Glargine was associated with progressive weight gain The most common adverse effects of Exenatide were GI-related, decreased in incidence throughout the study. Exenatide may be an effective alternative to starter basal insulin for type 2 diabetes sub-optimally controlled with MET + SU Heine R, et al. Ann Intern Med 2005;143:
17 Contraindications / precautions of GLP-1 Not recommended in moderate/severe renal impairment Pregnancy/breast feeding Type 1 Diabetes Pancreatitis Risk of Hypoglycaemia in combination with Sulphonylurea
18 Duration of diabetes Should we consider...? GLP-1 may be beneficial when used early in the treatment algorithm Ability and willingness to self-measure blood glucose if put on SU s or insulin GLP-1 require no additional blood glucose monitoring (unless on Sulphonylureas) Dosing flexibility Weight GLP-1 induce significant and sustained weight loss Cardiovascular risk Weight loss induced by GLP-1 may improve CV risk profile in overweight and obese type 2 diabetes patients
19 NICE- type 2 guidelines positioning for GLP-1 (Exenatide) Consider adding a GLP-1 mimetic (exenatide) as third-line therapy to first-line metformin and a second-line sulfonylurea when control of blood glucose remains or becomes inadequate A body mass index (BMI) 35.0 kg/m 2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or A BMI < 35.0 kg/m 2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related co morbidities. National Institute for Health and Clinical Excellence. Type 2 diabetes: Newer agents for blood glucose control in type 2 diabetes. Short Clinical Guideline 87. London: NICE; 2009 (
20 NICE Recommendation Only continue GLP-1 mimetic (Exenatide) therapy if the person has had a beneficial metabolic response a reduction of at least 1.0% in HbA1c & weight loss of at least 3.0% of initial body weight at 6 months.
21 Nice -Type 2 positioning for Insulin therapy Third line treatment option after Metformin / SU Should be initiated with a structured education programme If other measures do not keep HbA1c to <7.5% particularly if person is markedly hyperglycaemic Begin with human NPH insulin taken at bed time Twice daily should be considered if HbA1c >9.0% Consider a one daily long acting analogue (Detemir/Insulin Glargine) if the person needs support with injecting, does not reach target HbA1c due to hypoglycaemia or cannot use the delivery device for NPH National Institute for Health and Clinical Excellence. Type 2 diabetes: Newer agents for blood glucose control in type 2 diabetes. Short Clinical Guideline 87. London: NICE; 2009 ( 21
22 Insulin V s GLP-1 Insulin Appropriate treatment for Type 2 symptomatic patients with Hba1c >9% Considerations/Barriers Weight increase Titration of dose Driving/employment considerations Side effects GLP 1 Appropriate treatment for overweight Type 2 patients Considerations/Barriers Weight loss Minimal titration Less considerations re driving/employment Side effects Contra Indications
23 Female 54 yrs old Case Study 1 Shirley Admin support worker Type 2 Diabetes 4 yrs duration Referred from GP with deterioration in diabetes control HbA1c 8.7% (72mmol/mol) WT 148.6kgs BMI 52.9 Non Symptomatic Complications. Background retinopathy Medication Gliclazide 160mgs BD Metformin SR 2G daily Orlistat 120mgs TDS
24 Shirley Commenced on Exenatide Wt reduction 13.3Kgs HbA1c reduction 1.6% Weight Kg BMI HbA1c Start mts mts year
25 Case study 2 Richard Male 54 yrs old Lorry Driver Type 2 Diabetes 14yrs duration Referred to Diabetes Team with poor diabetes control HbA1c: 8%(64mmol/mol) Wt: BMI: 46.6 Complications: Background Retinopathy, Hyperlipidaemia, Hypertension Medication: Metformin 1G TDS Gliclazide 160mg BD. Rosiglitazone 8mg
26 Richard Commenced Exenatide Pioglitazone stopped Gliclazide reduced to 80mgs BD Wt reduction 9.9Kg HbA1c reduction 0.1% ( at 1 year) Weight Kg BMI Waist HbA1c Start mts mts year
27 Case Study 3 Frank 63 yrs Type 2 DM 5yrs Retired HbA1c 12.1%(109mmol/mol) Wt 87.8kgs BMI 29.7 Non symptomatic Complications: Background Retinopathy Diabetes Medication: Gliclazide 160mgs BD Pioglitazone/Metformin 15/850 1 BD
28 Frank Commenced Insulin Humulin Isophane 10units at bedtime Continued on Pioglitazone/Metformin and Gliclazide 3.9% drop in HbA1c 5.6kgs increase in weight Weight BMI HbA1c Kg Start mts mts mts
29 Case Study 4 Peter 68 yrs Type 2 DM 2 yrs Retired HbA1c 9.8%(84mmol/mol) Wt 72kgs BMI 24.9 Symptomatic: thirst, weight loss Complications : NAD Diabetes Medication: Gliclazide 160mgs BD Pioglitazone 45mgs OD Metformin SR 1G daily
30 Peter Commenced BD Pre Mixed Insulin 10 units BD Gliclazide & Pioglitazone stopped 1.2% drop in HbA1c at 1yr 4.2kg increase in weight Wt Kg BMI HbA1c % Start mts mts
31 Case study 5 Christine 59 yrs Type 2 DM -11 yrs duration HbA1c 8.8%(73mmol/mol) Wt BMI 35.8 Symptomatic lethargy Complications: CKD stage 4 (egfr 27, Creatinine 219mmol/l) Diabetes Medications: Gliclazide 160mgs BD Pioglitazone 30mgs OD
32 Christine Commenced basal insulin 10 units Humulin Isophane Gliclazide stopped 0.9% drop in HbA1c 1.8Kg weight increase Wt Kg BMI HbA1c % Start mts mts
33 Summary and conclusions Treatment needs to be patients focussed based on individual targets decided by the patient and clinician. GLP-1 therapies represents a therapeutic option for patients with type 2 diabetes especially where weight is an issue Considerations: Efficacy Significance of weight control for the individual patient Patient preference Practicalities of treatment initiation and administration Tolerability Kendall et al. Eur J Intern Med 2009;20:S329 S339
Workshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationType 2 Diabetes. Aims and Objectives. What did you consider? Case Study One: Miss S. Which to choose?!?! Modes of Action
Aims and Objectives This session will outline the increasing complexities of diabetes care, and the factors that differentiate the combinations of therapy, allowing individualisation of diabetes treatment.
More informationInitiate Atorvastatin 20mg daily
Type 2 Diabetes Patient Objectives Stopping Smoking BMI > 25 kg m² Control BP to
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationType 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB
Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Declarations I have received travel funding and speaker fees
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationGuideline for Insulin Therapeutic Review in patients with Type 2 Diabetes
Diabetes Sans Frontières Guideline for Insulin Therapeutic Review in patients with Type 2 Diabetes 1. Introduction This guideline has been developed in order to support practices to undertake insulin therapeutic
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More informationNew Treatments for Type 2 Diabetes
New Treatments for Type 2 Diabetes Dr David Hopkins Clinical Director, Division of Ambulatory Care King s College Hospital NHS Foundation Trust Treatments for type 2 diabetes - old & new insulin sulphonylureas
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationCancer treatment and diabetes
Cancer treatment and diabetes Dr Daniel Morganstein Consultant Endocrinologist, 1 2 Diabetes and cancer Cancer and its treatment also poses challenges to managing diabetes Surgery Altered appetite Cachexia
More informationLiraglutide for the treatment of type 2 diabetes
DOI: 10.3310/hta15suppl1/09 Health Technology Assessment 2011; Vol. 15: Suppl. 1 77 Liraglutide for the treatment of type 2 diabetes D Shyangdan, 1 * E Cummins, 2 P Royle 1 and N Waugh 1 1 Department of
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationInitiating & titrating insulin & switching in General Practice Workshop 1
Initiating & titrating insulin & switching in General Practice Workshop 1 Workshop goal To make participants comfortable in the timely initiation and titration of insulin Progression of Type 2 Diabetes
More informationDiabetes in Primary Care course MCQ Answers 2016
Diabetes in Primary Care course MCQ Answers 2016 Diagnosis of Diabetes HbA1C should not be used as a diagnostic tool in the following situations: (answer each TRUE or FALSE) 1. Gestational Diabetes TRUE
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationTYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES
TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin
More informationManaging the risks of commencing insulin therapy for patients with type 2 diabetes
Managing the risks of commencing insulin therapy for patients with type 2 diabetes Laila King June 213 213 The Health Foundation Insulin is a remedy primarily for the wise, and not for the foolish, whether
More informationEvaluation of: The Local Enhanced Service provision of for Managing Diabetes Injectable Therapies
Evaluation of: The Local Enhanced Service provision of for Managing Diabetes Injectable Therapies Two CCGs have asked the WSYBCSU to evaluate the current Local Enhanced Service (LES) provision in this
More informationlinagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd
linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationTrends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
More informationInsulin use in Type 2 Diabetes. Dr Rick Cutfield. Why? When? How?
Insulin use in Type 2 Diabetes Dr Rick Cutfield Why? When? How? 1 Conflict of Interest I have been on advisory boards or had speaker fees from the following pharmaceutical companies: - Eli Lilly - Novo
More informationClinical Assistant Professor. Clinical Pharmacy Specialist Wesley Family Medicine Residency Program. Objectives
What s New in Diabetes Medications? Matthew Kostoff, PharmD, BCPS, BCACP Clinical Assistant Professor Clinical Pharmacy Specialist Wesley Family Medicine Residency Program Objectives Discuss new literature
More informationCochrane Quality and Productivity topics
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationInsulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
More informationUsing human insulin in line with the NICE guideline on type 2 diabetes:
Using human insulin in line with the NICE guideline on type 2 diabetes: Inside: Insulin initiation in type 2 diabetes: What should we be doing? Matthew Oldfield Human insulin in clinical practice: A series
More informationTYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS
TYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS The aim of the Diabetes level 2 service is to provide a high quality service for safe initiation and optimization of injectable therapy within GP networks.
More informationInsulin Treatment. J A O Hare. www.3bv.org. Bones, Brains & Blood Vessels
Insulin Treatment J A O Hare www.3bv.org Bones, Brains & Blood Vessels Indications for Insulin Treatment Diabetic Ketoacidosis Diabetics with unstable acute illness ICU Gestational Diabetes: diet failure
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationJill Malcolm, Karen Moir
Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are
More informationAre insulin analogs worth their cost in type 2 diabetes?
Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationof Treatment Options for Type 2 Diabetes Patients
Guidance Pack East Surrey CCG Guildford & Waverley CCG North West Surrey CCG Surrey Downs CCG Surrey Heath CCG North East Hampshire & Farnham CCG Crawley CCG Horsham & Mid-Sussex CCG of Treatment Options
More informationUser guide Basal-bolus Insulin Dosing Chart: Adult
Contacts and further information Local contact Clinical pharmacy or visiting pharmacy Diabetes education service Director of Medical Services Visiting or local endocrinologist or diabetes physician For
More informationSubcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes
Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes Mario R. Ehlers, 1,2 Roderick E. Harley, 1 Annette L. Mathisen, 1 Roberta Schneider,
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationScottish Medicines Consortium
Scottish Medicines Consortium insulin glulisine for subcutaneous injection 100 units/ml (Apidra ) No. (298/06) Sanofi Aventis 4 August 2006 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationDIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS
Section Two DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS This section will: Describe oral agents (pills) are specific for treating type 2 diabetes. Describe other hypoglycemic agents used
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More informationLeicestershire Diabetes Guidelines: Insulin Therapy
Endorsed by Leicestershire Medicines Strategy Group Leicestershire Diabetes Guidelines: Insulin Therapy These guidelines are designed for use by those trained and competent in insulin initiation and management
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationType 2 diabetes mellitus
Type 2 diabetes mellitus CLINICAL PRACTICE Management Guidelines for initiating insulin therapy BACKGROUND Insulin is often indicated for patients with suboptimally controlled type 2 diabetes mellitus,
More informationA Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes
A Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes 1. Summary... 1 2. Background... 2 3. Purpose 2 4. Responsibilities. 2 5. Blood Glucose Monitoring. 2 6. Resident Groups that
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationINSULIN INITIATION IN TYPE 2 DIABETES IN PRIMARY CARE
INSULIN INITIATION IN TYPE 2 DIABETES IN PRIMARY CARE We welcome feedback on this policy and the way it operates. We are interested to know of any possible or actual adverse impact that this policy/procedure
More informationDiabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.
Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact
More informationThe GP Update Handbook Spring 2013
The GP Update Handbook Spring 2013 www.gp-update.co.uk GP Update Limited Type 2 Diabetes NICE and SIGN guidelines for type 2 diabetes...58 Diagnostic criteria for type 2 diabetes and pre-diabetes...58
More informationType 2 Diabetes - Referral Criteria to Specialist Services
Diabetes Pathway Contact Tel: 023 8028 6401 Fax: 023 8028 6407 Mon-Fri 9.00am-5.00pm Email: hp-tr.diabetes@nhs.net Consultants email: kate.fayers@southernhealth.nhs.uk hermione.price@southernhealth.nhs.uk
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationType 2 Diabetes workshop notes
Group 1 notes Abi / Nicole Type 2 Diabetes workshop notes 4.1 Population The group discussed the following sub groups that may need addressing: Men-as they tend to die earlier compared with women, their
More informationAntihyperglycemic Agents Comparison Chart
Parameter Metformin Sulfonylureas Meglitinides Glitazones (TZD s) Mechanism of Action Efficacy (A1c Reduction) Hepatic glucose output Peripheral glucose uptake by enhancing insulin action insulin secretion
More informationGlycaemic Control in Adults with Type 1 Diabetes
Glycaemic Control in Adults with Type 1 Diabetes Aim(s) and objective(s) This document aims to provide guidance on good clinical practice in managing glycaemic control in adult patients with Type 1 Diabetes
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationInsulin therapy in type 2 diabetes When and how? Disclosures. Learning Objectives. None relevant to today s talk
Insulin therapy in type 2 diabetes When and how? Cecilia C Low Wang, MD Univ Colorado AMC SOM Department of Medicine Division of Endocrinology, Metabolism, and Diabetes Disclosures None relevant to today
More informationType 2 Diabetes. Management and Medication. HELPLINE: 01604 622837 www.iddtinternational.org
I N D E P E N D E N T D I A B E T E S T R U S T Type 2 Diabetes Management and Medication A charity supporting and listening to people who live with diabetes HELPLINE: 01604 622837 www.iddtinternational.org
More informationNewcastle Mitochondrial Disease Guidelines
Newcastle Mitochondrial Disease Guidelines Diabetes Mellitus in Adult Mitochondrial Disease: Screening and Initial Management First published March 2013 Updated December 2013 1 Contents Introduction 4
More informationPresented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More informationLead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:
Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus
More informationPersonalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach
Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Riccardo Candido on behalf of the Personalized Therapy AMD Study Group Diabetes Canter A.S.S. 1 Triestina, Italy BACKGROUND
More informationDIABETES - INSULIN INITIATION - BACKGROUND INFORMATION (1)
DIABETES - INSULIN INITIATION - BACKGROUND INFORMATION (1) KEY PRINCIPLES Many patients with Type 2 diabetes will require insulin therapy. In the UKPDS over 50% of patients by 6 years required additional
More informationHow To Treat Diabetes
Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in
More informationUnderstanding Your Diabetes HELPLINE: 01604 622837 www.iddtinternational.org
I ndepend ent DI abetes t rust Understanding Your Diabetes HELPLINE: 01604 622837 www.iddtinternational.org INDEPENDENT DIABETES TRUST The Trust offers support, understanding and information to people
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More information2011: New Drugs for Diabetes Treatment
Cardiology Update 2011 Davos, February 14, 2011 2011: New Drugs for Diabetes Treatment Roger Lehmann Department of Unresolved Problems in the Treatment of Type 2 Diabetes Diabetes Duration Consequences:
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationStarting Insulin Sooner Than Later
Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration
More informationEndocrine Disorders. Diabetes Meds Objectives. Diabetes Type 1 and Type 2. Insulin Dynamics. Insulin is all about timing! Rapid acting insulin O P D
Endocrine Disorders Diabetes Meds Objectives Explain the action of the various types of insulin currently available Identify the relationship between insulin peak and risk for hypoglycemia Discuss rationale
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationTreatment of patients with type 2 diabetes: from text book therapy to personalized medicine
1 Treatment of patients with type 2 diabetes: from text book therapy to personalized medicine BruceH H.R. Wolffenbuttel, MDPhD Professor of Endocrinology & Metabolism University Medical Center Groningen
More informationType 2 Diabetes. Tabinda Dugal GP Day 4/05/16
Type 2 Diabetes Tabinda Dugal GP Day 4/05/16 Diabetes Diabetes.a growing health crisis in Britain 869m per year 10% of NHS budget Projections.. 5 million by 2025 Youngest patient? T2DM Type 2 diabetes
More informationMedication Review. What is Diabetes? Medications. Michelle Weddell. Business Development Executive Clinical Specialist Podiatrist
Medication Review Michelle Weddell Business Development Executive Clinical Specialist Podiatrist What is Diabetes? What is a type 1 diabetic? What is type 2 diabetic? Is there other forms of diabetes?
More informationMary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
More informationOverview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU
Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationNewer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013
Newer Anticoagulants and Newer Diabetic Drug Classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Apixaban Newer Anticoagulants Dabigatran etexilate Rivaroxaban
More informationPharmaceutical Management of Diabetes Mellitus
1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal
More informationBIAsp30 A 1 chieve Tehran 31 July 2015
BIAsp30 A 1 chieve Tehran 31 July 2015 Beginning insulin with biphasic insulin aspart 30: experience from the A 1 chieve study Professor Philip Home Newcastle University Presenter and sponsor duality of
More informationUpdate on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationEffect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
More informationExenatide (Byetta) for type 2 diabetes
Exenatide (Byetta) for type 2 diabetes This Medicine Update is for people who are using, or thinking about using, exenatide. Summary Exenatide is a new injectable medicine that reduces blood glucose levels.
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationGlobal Guideline for Type 2 Diabetes
INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication
More informationPrescribing for type 2 diabetes in the elderly: issues and solutions
Prescribing for type 2 diabetes in the elderly: issues and solutions Roger Gadsby MBE, BSc, DRCOG, DCH, FRCGP Debbie Hicks MSc, BA, RGN, NMP, DN Cert, PWT Cert Richard Holt MA, PhD, FRCP, FHEA Over half
More informationType 2 Diabetes - Pramlintide and Exenatide
Therapies for Diabetes: Pramlintide and Exenatide MELISSA C. JONES, PharmD, BCPS, South University School of Pharmacy, Savannah, Georgia The American Diabetes Association currently recommends an A1C goal
More information